Mocertatug Rezetecan

瑞康莫赛妥塔单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameMocertatug Rezetecan
Drug Alias NameHS-20089GSK-5733584GSK5733584
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payload
Mechanisms of ActionAnti-V-set domain-containing T-cell activation inhibitor 1DNA topoisomerase I inhibitors
TargetsV-set domain-containing T-cell activation inhibitor 1DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsEndometrial Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaPanama +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Hansoh Biomedical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGlaxosmithkline PlcJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsEndometrial Neoplasms +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A